With its fourth biosimilar approval, FDA has once again shown that its thinking about how to label such products continues to evolve.
In the case of Amgen Inc.'s Amjevita (adalimumab-atto), FDA took the opportunity to adjust its biosimilar labeling approach on indications for which the reference product sponsor still holds exclusivity.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?